Precision in Pharmacoeconomics: A Comparative Cost-Utility Analysis of Osimertinib in EGFR-Mutant NSCLC Using Traditional and Pharmacometric Models

View at publisher Summarise with VIRAT
Authors: Gloria Nnadwa Alhassan
Cited by: 0
References: 49

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Fields of Study & Subjects

Health Systems Economic Evaluations Quality of Life Lung Cancer Treatments and Mutations Pharmaceutical Economics and Policy

Publication details

Journal / source
Therapeutic Innovation & Regulatory Science
Volume
60
Issue
4
Pages
1084–1093
Publication date
28 March 2026
Language
EN